# Pomalidomide as an Immune-enhancing Agent for the Control of HIV

> **NCT06660498** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Aarhus** · enrollment: 32 (estimated)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Pomalidomide 2 mg
- **DRUG:** Placebo
- **DRUG:** Aspirin 75 mg

## Key facts

- **NCT ID:** NCT06660498
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660498, "Pomalidomide as an Immune-enhancing Agent for the Control of HIV". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06660498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*